Circumscribed Choroidal Hemangioma in a Chinese Patient Treated using Transpupillary Thermotherapy: A Case Report  by Wang, Jia-Kang et al.
Choroidal hemangioma and transpupillary thermotherapy
Kaohsiung J Med Sci September 2005 • Vol 21 • No 9 433
Circumscribed choroidal hemangioma (CCH) is a benign
intraocular tumor. It may produce subretinal fluid to
cause foveal detachment, which results in visual
disturbance. Traditionally, argon laser photocoagulation
(ALP) has been the treatment of choice. Retinal detachment
recurs in a segment of patients treated using ALP [1].
In recent years, outcomes in patients with CCH treated
using transpupillary thermotherapy (TTT) have been fair
[2–8]. TTT uses 810-nm diode laser infrared radiation with
a long pulse duration, large spot size, and low irradiance.
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We describe the first case of a Chinese patient with circumscribed choroidal hemangioma (CCH) effectively
managed using transpupillary thermotherapy (TTT). A 57-year-old man had an elevated orange-red
subretinal mass with a base of 5 × 5 mm superior to the optic disc, along with serous macular detachment
in the left eye. Ultrasonography depicted a mass 3 mm thick with acoustic solidity and high internal
reflectivity. Fluorescein angiography showed an area of hyperfluorescence in the prearterial phase and
tumor staining in the late phase, consistent with a diagnosis of CCH. Therefore, TTT (spot size, 3 mm;
exposure, 1 min) was performed with a diode laser, delivered through a slit-lamp biomicroscope. The laser
power was first set at 300 mW and then increased in 50-mW increments, until test shots in the mid-peripheral
retina outside the lesion produced a slightly grayish appearance in the irradiated area. The tumor was
covered with four overlapping laser spots and subjected to an average beam power of 400 mW. Best-
corrected visual acuity increased from 20/50 before treatment, to 20/20 3 months following one session of
TTT. The lesion became atrophic and the subretinal fluid disappeared. Our experience shows that TTT can
be an even more effective treatment strategy for CCH in Asians than in Caucasians. In Chinese patients, the
power level of the diode laser should be lower than that used in Caucasians.
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The diode laser delivers low-dose heat to the deeper layers
of the retina and choroid, inducing tumor vessel oblit-
eration and resorption of subretinal fluid [5]. However,
the power setting of the diode laser depends on iris color
and pigmentation of the fundus, which is determined
by race [9,10]. To date, most cases of CCH treatment with
TTT have been reported in Caucasians [3–8]. Because
Asians, including Chinese, have dark brown irises and
heavily pigmented fundi, the effective power needed for
treatment is theoretically lower in Asians than in
Caucasians. We demonstrate how lower power can be
used in Asians to cause effective tumor resolution. To our
knowledge, TTT to manage CCH in Chinese patients has
yet to be reported. In this article, we describe our initial
experience of one case of CCH in a Chinese patient treated
with TTT.
© 2005 Elsevier. All rights reserved.
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CASE PRESENTATION
A 57-year-old man complained of blurred vision in the left
eye for 10 days. His best-corrected visual acuity (BCVA)
was 20/50 in the left eye, and 20/20 in the right. Anterior
segment examination and intraocular pressure were
normal in both eyes. Both lenses were clear. No fundus
abnormalities were noted in the right eye. The patient had
brown irises and heavy fundus pigmentation. An elevated
orange-red subretinal mass with a base of 5 × 5 mm was
found superior to the optic disc on ophthalmoscopic
examination (Figure 1). Serous macular detachment was
also discovered. Ultrasonography depicted a mass 3 mm
thick with acoustic solidity (Figure 2). Fluorescein
angiography showed hyperfluorescence in the prearterial
phase and tumor staining in the late phase, consistent with
a diagnosis of CCH (Figure 3). Therefore, TTT was
performed under topical anesthesia and dilated pupil
conditions. The diode laser (Iris Medical Instruments,
Mountain View, CA, USA) was delivered through a slit
lamp, which was focused on the lesion with a Volk Area
Centralis contact lens. The spot size was 3 mm and the
exposure time of each spot was 1 minute. The laser power
was first set at 300 mW and then adjusted in 50-mW
Figure 1. Fundus picture shows an elevated orange-red subretinal mass
superior to the optic disc. Figure 3. Fluorescein angiography shows marked hyperfluorescence in
the tumor.
Figure 4. Fluorescein angiography reveals mottled hyperfluorescence
and hypofluorescence in the atrophic circumscribed choroidal
hemangioma.
Figure 2. B-mode ultrasonogram demonstrates a 3-mm-thick mass with
acoustic solidity.
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increments until test shots resulted in a slightly grayish
appearance in the irradiated area of the mid-peripheral
retina outside the lesion. The tumor was covered with four
overlapping laser spots and subjected to an average beam
power of 400 mW. The patient’s BCVA recovered to 20/20
by 3 months after one session of TTT. The lesion became
atrophic and the associated subretinal fluid completely
resolved (Figure 4). The choroidal mass was not found on
ultrasonography after TTT. The lesion and subretinal fluid
had not recurred by 1-year follow-up.
DISCUSSION
CCH presents as an orange-red subretinal mass, which can
be silent or cause serous retinal detachment. Fluorescein
angiography demonstrates areas of prearterial hyper-
fluorescence, while ultrasonography reveals acoustic
solidity and moderate-to-high reflectivity. In our case, CCH
was diagnosed from typical presentations on fluorescein
angiography, ultrasonography, and fundus pictures. Visual
deterioration resulted from subretinal fluid produced by
the CCH, which was the indication for intervention.
ALP is useful to eliminate subretinal fluid [1]. It is
noninvasive and is associated with few complications.
However, because it achieves only superficial coagulative
effects and damages the treated retinal area, it does not
cause regression of CCH. In 40% of CCH cases treated
using ALP, subsequent re-accumulation of subretinal
fluid is possible, and repeated sessions of treatment are
required [1]. Some patients (such as those with bullous,
large-area retinal detachment) are not eligible for ALP.
Radiotherapy is another possible treatment, but it may
result in secondary cataract and/or retinopathy, and is not
widely available [2].
In 1999, Othmane et al first used TTT as a secondary
treatment in a case of CCH, after subretinal fluid failed to
resolve following ALP [4]. Subsequently, Garcia-Arumi et
al introduced TTT as a primary treatment for CCH [3]. An
810-nm infrared diode laser is used in TTT. The retinal
pigment epithelium (RPE) absorbs only about 12% of the
coherent infrared light at the 810-nm frequency (i.e. more
diode laser light than argon laser light penetrates the RPE
into the choroid, and the focus of the thermal damage lies
mainly in the uvea ) [9]. The technique uses a wide diode
laser beam diameter (2–3 mm) with a long exposure time
per application (1 minute for each spot) and low irradiance
(800–1,200 mW) [3]. The protocol produces optimal heat
penetration, and not the coagulative effect generated by the
argon laser. Temperature in the retina and RPE is raised by
approximately 8–10°C following TTT, instead of the
20–40°C following ALP [11]. Therefore, TTT delivers low-
dose heat to the deeper layers of the retina and choroid,
inducing sclerosis of the vascular channels, and resulting in
tumor regression and resolution of the associated fluid in
CCH patients [2]. A review of 38 cases of CCH treated with
TTT concluded that anatomic results were good [2]. Serous
retinal detachment resolved in all patients, and tumor
regression was demonstrated in 95% of patients.
Complications (only observed in 1 or 2 patients) were
minimal and transient and included small branch retinal
vein occlusion, cystoid macular edema, and preretinal
fibrosis [2,5]. We successfully used TTT to treat a patient
with CCH. Tumor regression was observed, and subretinal
fluid resolved completely. The patient did not encounter
any side effects.
In a previous study of diode laser photocoagulation,
Isola et al found marked differences in laser power levels in
eyes with different iris colors and fundi pigmentations [9].
In eyes with more iris and fundus pigmentation, lower
diode laser power was sufficient for threshold burn.
Connolly et al described the histopathologic effects of TTT
in human eyes [10]. The likelihood of producing an
undesirable degree of neurosensory retinal damage in a
normal human eye seems to be high if the fundus
pigmentation is relatively prominent. Because radiant
energy emitted from a diode laser is absorbed by melanin
within the RPE and choroid, the power output correlates
with ocular pigmentation [9]. Caucasians have lightly
pigmented fundi. In three reports about TTT in the primary
management of CCH in the West, a power level of more
than 700 mW was used with 3-mm spot diameter [3,5,6].
Fuchs et al described 10 eyes with CCH in Germany, treated
primarily using TTT, and mentioned that TTT was delivered
at power settings of 300–1,100 mW [8]. However, the spot
size varied () 3 mm). The exact level of laser irradiation
cannot be determined from this study [8].
Asians, especially Chinese, have dark brown irises and
deeply pigmented fundi. Accordingly, the effective power
used to treat CCH with TTT should be lower in Chinese
than in Caucasians. This was the first case of CCH treated
using TTT in Chinese, and the appropriate power setting
had not been established. We, therefore, cautiously adjusted
the power level using test shots in the mid-peripheral retina
outside the tumor, to prevent excessive exposure to the
diode laser light. A power setting of only 400 mW (much
lower than that used in Caucasians) was enough to turn the
lesion a faintly gray-white color and cause tumor regression.
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Therefore, power output must be adjusted during TTT in
Asians, either for treatment of CCH or other applications
such as choroidal neovascularization. Our patient was suc-
cessfully treated using only one session of TTT. In contrast,
one to three sessions of TTT were needed for complete
management in Western reports [3,5,8]. This suggests that
TTT is more effective for CCH in Asians than in Caucasians.
In conclusion, TTT may be a more effective treatment for
CCH in Asians than in Western patients. In Chinese patients,
the power level of the diode laser should be lower than the
levels used in Caucasians.
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